The role of CTLA4-Ig in a mouse model against allergic asthma.
- Author:
Huanying WAN
1
;
Min ZHOU
;
Qing XU
;
Shaoguang HUANG
;
Weiwu DENG
Author Information
- Publication Type:Journal Article
- MeSH: Abatacept; Animals; Asthma; immunology; pathology; therapy; Immunoconjugates; therapeutic use; Interleukin-4; blood; Leukocyte Count; Mice; Mice, Inbred BALB C; Trachea; pathology
- From: Chinese Medical Journal 2003;116(3):462-464
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate CTLA4-Ig's potential role in therapy for allergic asthma by blocking B7/CD28 interactions with cytotoxic T lymphocyte antigen 4-Ig (CTLA4-Ig).
METHODSWe divided BALB/C mice into the three groups: Sham/Sham (control), ovalbumin (OVA)/OVA and mCTLA4-Ig. Blood, bronchoalveolar lavage, histology and determination of cytokines were performed 24 hours after airway challenge.
RESULTSIn the OVA/OVA group, the number of cells, the percentage of inflamed cells and the level of IL-4 in BALF were increased. Airways in our murine model for allergic asthma underwent pathological changes, which were significantly reduced after treatment with mCTLA4-Ig.
CONCLUSIONBlockage of co-stimulation with mCTLA4-Ig can inhibit allergy-specific response of T cells, and asthmatic response as well.
